Genetic control of complement activation in humans and age related macular degeneration

10Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The major focus of our research is to understand how age-related macular degeneration (AMD) develops. It is known that genetic variation can explain much of the risk of developing AMD. However, we do not know what controls the transition between a normal fundus and the extensive accumulation of subretinal inflammatory material that we recognize as drusen in AMD. We do know that the accumulation of this inflammatory material that characterizes the maculopathy underlying AMD is by far the most important predictor of late AMD. Late or advanced forms of AMD include geographic atrophy in which there is patchy death of the retina and exudation in which abnormal neovascularization invades the subretinal or subretinal pigment epithelial space. Thus, preventing the accumulation of the inflammatory debris underneath the retina could be expected to alleviate much of the vision loss from this devastating disease. © Springer Science+Business Media, LLC 2010.

Cite

CITATION STYLE

APA

Hecker, L. A., & Edwards, A. O. (2010). Genetic control of complement activation in humans and age related macular degeneration. Advances in Experimental Medicine and Biology, 703, 49–62. https://doi.org/10.1007/978-1-4419-5635-4_4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free